HBsAg, Anti-Hepatitis C Virus and Anti-HIV Seroprevalence Among Patients Admitted to Our Hospital between 2005 and 2013

Avcıküçük, Havva; Süzük, Serap; Kavak, Mehmet

doi:10.4274/vhd.29190

Cited by 1 publication

(1 citation statement)

References 6 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These rates were slightly higher than those in our study. In another Turkish study including a large study sample, Avcıküçük et al [30] determined rates of HBsAg, anti-HCV, and anti-HIV positivity as 2.21%, 0.56%, and 0.0008%. As for the distributions of seropositivity rates according to sex, females accounted for 39.42% of HBsAg-positive and 53.48% of anti-HCV-positive subjects.…”

Section: Discussionmentioning

confidence: 99%

HBsAg, Anti-HCV and Anti-HIV Seroprevalence Among Patients Admitted to State Hospital between 2014 and 2018

Bilman¹

2019

mjima

View full text Add to dashboard Cite

The epidemiology of viral hepatitis and human immunodeficiency virus (HIV) infections has been changing worldwide and in Turkey. The aim of this study was to present current information about seropositivity rates in hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV), and anti-HIV test results according to gender, age, and other risk factors (dialysis, preoperative tests, outpatient clinics) in patients aged 1-99 who presented to the İzmir Menemen State Hospital between January 2014 and July 2018. Materials and Methods: During the study period, 58,752 samples were tested for HBsAg, 53,649 samples for anti-HCV, and 48,162 samples for anti-HIV by chemiluminescence immunoassay method by using HBsAg 2, anti-HCV 2 and HIV combi PT kits in a Roche Modular E170 device (Roche Diagnostics GmbH, Penzberg, Germany). Data were collected retrospectively from the microbiology laboratory database. Results: The seropositivity rates for HBsAg, anti-HCV, and anti-HIV were 4.75% (2790/58,752), 0.7% (376/53,649), and 0.02% (11/48,162), respectively. The mean age of patients with HCV seropositivity was significantly higher (57±10 years) than patients with hepatitis B virus (HBV) seropositivity (41±13 years). Hepatitis B surface antigen and anti-HCV seropositivity rates were significantly higher in dialysis patients (8.7% and 10%, respectively) than in the other groups. Of the HBsAg-positive individuals, 74 (2.65%) were born between 1999 and 2007 (HBV vaccine was added to the routine vaccination program in Turkey in 1998) and only 1 (0.03%) was born after 2007 (the year that family medicine practice was implemented in İzmir province). The other 2,715 HBsAg-positive individuals (97.32%) were born in or before 1998. Conclusion: The seropositivity rates for HBsAg and anti-HCV in our region were found to be compatible with other regions. Monitoring changes in regional data and surveillance studies are important for HBV, HCV, and HIV infections and seropositivity rates.

show abstract

Section: Discussionmentioning

confidence: 99%